ReviewJournal of pharmaceutical analysis2021
Protecting future antimalarials from the trap of resistance: Lessons from artemisinin-based combination therapy (ACT) failures.
Review in Journal of pharmaceutical analysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Eugenol-based carbazole-triazole derivative 5m exhibits potent anti-plasmodial activity associated with predicted plasmepsin II binding and oxidative stress in chloroquine-resistant Plasmodium falciparum.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Efficacy of artemether-lumefantrine combination for the treatment of uncomplicated Plasmodium falciparum malaria after 16 years of its introduction into Ghana's antimalarial medicines policy.Malaria journal · 2026Article
- Insights into Malaria and HIV Co-infection: Trends and Impact in Sub-Saharan Africa.Current HIV research · 2026Review
- Polymeric microarray patches for transdermal delivery of amodiaquine and artesunate: A novel strategy againstMaterials today. Bio · 2025Article
- Computational insights into harmala alkaloids as novel antimalarial candidates against Plasmodium falciparum.Scientific reports · 2025Article
- Review
- Identification of Malaria-Selective Proteasome β5 Inhibitors Through Pharmacophore Modeling, Molecular Docking, and Molecular Dynamics Simulation.International journal of molecular sciences · 2024Article
- Recent Advances in the Treatment of Malaria.Pharmaceutics · 2024Review
- Chloroformate-mediated ring cleavage of indole alkaloids leads to re-engineered antiplasmodial agents.Organic & biomolecular chemistry · 2024Article
- In vitro and in vivo antiplasmodial activity of a synthetic dihydroartemisinin-eosin B hybrid.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Novel quinolinepiperazinyl-aryltetrazoles targeting the blood stage ofRSC medicinal chemistry · 2024Article
- Efficacies and ADME properties of redox active methylene blue and phenoxazine analogues for use in new antimalarial triple drug combinations with amino-artemisinins.Frontiers in pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Having faced increased clinical treatment failures with dihydroartemisinin-piperaquine (DHA-PPQ), Cambodia swapped the first line artemisinin-based combination therapy (ACT) from DHA-PPQ to artesunate-mefloquine given that parasites resistant to piperaquine are susceptible to mefloquine. However, triple mutants have now emerged, suggesting that drug rotations may not be adequate to keep resistance at bay. There is, therefore, an urgent need for alternative treatment strategies to tackle resistance and prevent its spread. A proper understanding of all contributors to artemisinin resistance may help us identify novel strategies to keep artemisinins effective until new drugs become available for their replacement. This review highlights the role of the key players in artemisinin resistance, the current strategies to deal with it and suggests ways of protecting future antimalarial drugs from bowing to resistance as their predecessors did.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.